Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity
1. Various types of anticholinesterasic agents have been used to improve the daily activities of Alzheimer's disease patients. It was recently demonstrated that Galantamine, described as a molecule with anticholinesterasic properties, is also an allosteric enhancer of human alpha4beta2 neuronal...
Gespeichert in:
Veröffentlicht in: | British journal of pharmacology 2005-07, Vol.145 (5), p.672-678 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 678 |
---|---|
container_issue | 5 |
container_start_page | 672 |
container_title | British journal of pharmacology |
container_volume | 145 |
creator | Texidó, Laura Ros, Esteve Martín-Satué, Mireia López, Susana Aleu, Jordi Marsal, Jordi Solsona, Carles |
description | 1. Various types of anticholinesterasic agents have been used to improve the daily activities of Alzheimer's disease patients. It was recently demonstrated that Galantamine, described as a molecule with anticholinesterasic properties, is also an allosteric enhancer of human alpha4beta2 neuronal nicotinic receptor activity. We explored its effect on the human alpha7 neuronal nicotinic acetylcholine receptor (nAChR) expressed in Xenopus oocytes. 2. Galantamine, at a concentration of 0.1 microM, increased the amplitude of acetylcholine (ACh)-induced ion currents in the human alpha7 nAChR expressed in Xenopus oocytes, but caused inhibition at higher concentrations. The maximum effect of galantamine, an increase of 22% in the amplitude of ACh-induced currents, was observed at a concentration of 250 microM Ach. 3. The same enhancing effect was obtained in oocytes transplanted with Torpedo nicotinic acetylcholine receptor (AChR) isolated from the electric organ, but in this case the optimal concentration of galantamine was 1 microM. In this case, the maximum effect of galantamine, an increase of 35% in the amplitude of ACh-induced currents, occurred at a concentration of 50 microM ACh. 4. Galantamine affects not only the activity of post-synaptic receptors but also the activity of nerve terminals. At a concentration of 1 microM, quantal spontaneous events, recorded in a cholinergic synapse, increased their amplitude, an effect which was independent of the anticholinesterasic activity associated with this compound. The anticholinesterasic effect was recorded in preparations treated with a galantamine concentration of 10 microM. 5. In conclusion, our results show that galantamine enhances human alpha7 neuronal nicotinic ACh receptor activity. It also enhances muscular AChRs and the size of spontaneous cholinergic synaptic events. However, only a very narrow range of galantamine concentrations can be used for enhancing effects. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67992065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67992065</sourcerecordid><originalsourceid>FETCH-LOGICAL-p543-f70bcab86f43ad893cccec9c35a977c4186b4fe23cbc3f3d3f4134cbc0eb6c6b3</originalsourceid><addsrcrecordid>eNqFkMFOwzAMhnsAsTF4BZQTJyqlS9q0RzQNmDSJy-5V6jprUZqEJEXqU_GKlG2cudiy9H229V8lS0qpSLOsLBfJbQgflGZciPwmWWR5yTjnbJl8b5VCiMQqcpRamiiH3iCxhsQOSTcO0hCpXScFMTh6a6Qmpgcb-7kSCRgnDZ3Vv5JHQBetfzq5B-sdtvZfmkjTkuDsfNqgHQO5AP44K2Ey0sWTG_uvPk53ybWSOuD9pa-Sw8v2sHlL9--vu83zPnU5Z6kStAHZlIXiTLZlxQAAoQKWy0oI4FlZNFzhmkEDTLGWKZ4xPg8UmwKKhq2Sx_Na5-3niCHWQx8AtT7_WBeiqta0yGfw4QKOzYBt7Xw_SD_VfwmzHy50fZs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67992065</pqid></control><display><type>article</type><title>Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Texidó, Laura ; Ros, Esteve ; Martín-Satué, Mireia ; López, Susana ; Aleu, Jordi ; Marsal, Jordi ; Solsona, Carles</creator><creatorcontrib>Texidó, Laura ; Ros, Esteve ; Martín-Satué, Mireia ; López, Susana ; Aleu, Jordi ; Marsal, Jordi ; Solsona, Carles</creatorcontrib><description>1. Various types of anticholinesterasic agents have been used to improve the daily activities of Alzheimer's disease patients. It was recently demonstrated that Galantamine, described as a molecule with anticholinesterasic properties, is also an allosteric enhancer of human alpha4beta2 neuronal nicotinic receptor activity. We explored its effect on the human alpha7 neuronal nicotinic acetylcholine receptor (nAChR) expressed in Xenopus oocytes. 2. Galantamine, at a concentration of 0.1 microM, increased the amplitude of acetylcholine (ACh)-induced ion currents in the human alpha7 nAChR expressed in Xenopus oocytes, but caused inhibition at higher concentrations. The maximum effect of galantamine, an increase of 22% in the amplitude of ACh-induced currents, was observed at a concentration of 250 microM Ach. 3. The same enhancing effect was obtained in oocytes transplanted with Torpedo nicotinic acetylcholine receptor (AChR) isolated from the electric organ, but in this case the optimal concentration of galantamine was 1 microM. In this case, the maximum effect of galantamine, an increase of 35% in the amplitude of ACh-induced currents, occurred at a concentration of 50 microM ACh. 4. Galantamine affects not only the activity of post-synaptic receptors but also the activity of nerve terminals. At a concentration of 1 microM, quantal spontaneous events, recorded in a cholinergic synapse, increased their amplitude, an effect which was independent of the anticholinesterasic activity associated with this compound. The anticholinesterasic effect was recorded in preparations treated with a galantamine concentration of 10 microM. 5. In conclusion, our results show that galantamine enhances human alpha7 neuronal nicotinic ACh receptor activity. It also enhances muscular AChRs and the size of spontaneous cholinergic synaptic events. However, only a very narrow range of galantamine concentrations can be used for enhancing effects.</description><identifier>ISSN: 0007-1188</identifier><identifier>PMID: 15834443</identifier><language>eng</language><publisher>England</publisher><subject>alpha7 Nicotinic Acetylcholine Receptor ; Animals ; Cholinesterase Inhibitors - pharmacology ; Female ; Galantamine - pharmacology ; Humans ; In Vitro Techniques ; Membrane Potentials - drug effects ; Nootropic Agents - pharmacology ; Oocytes - drug effects ; Parasympathetic Nervous System - drug effects ; Patch-Clamp Techniques ; Receptors, Nicotinic - drug effects ; Synapses - drug effects ; Synaptic Transmission - drug effects ; Torpedo ; Xenopus laevis</subject><ispartof>British journal of pharmacology, 2005-07, Vol.145 (5), p.672-678</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15834443$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Texidó, Laura</creatorcontrib><creatorcontrib>Ros, Esteve</creatorcontrib><creatorcontrib>Martín-Satué, Mireia</creatorcontrib><creatorcontrib>López, Susana</creatorcontrib><creatorcontrib>Aleu, Jordi</creatorcontrib><creatorcontrib>Marsal, Jordi</creatorcontrib><creatorcontrib>Solsona, Carles</creatorcontrib><title>Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>1. Various types of anticholinesterasic agents have been used to improve the daily activities of Alzheimer's disease patients. It was recently demonstrated that Galantamine, described as a molecule with anticholinesterasic properties, is also an allosteric enhancer of human alpha4beta2 neuronal nicotinic receptor activity. We explored its effect on the human alpha7 neuronal nicotinic acetylcholine receptor (nAChR) expressed in Xenopus oocytes. 2. Galantamine, at a concentration of 0.1 microM, increased the amplitude of acetylcholine (ACh)-induced ion currents in the human alpha7 nAChR expressed in Xenopus oocytes, but caused inhibition at higher concentrations. The maximum effect of galantamine, an increase of 22% in the amplitude of ACh-induced currents, was observed at a concentration of 250 microM Ach. 3. The same enhancing effect was obtained in oocytes transplanted with Torpedo nicotinic acetylcholine receptor (AChR) isolated from the electric organ, but in this case the optimal concentration of galantamine was 1 microM. In this case, the maximum effect of galantamine, an increase of 35% in the amplitude of ACh-induced currents, occurred at a concentration of 50 microM ACh. 4. Galantamine affects not only the activity of post-synaptic receptors but also the activity of nerve terminals. At a concentration of 1 microM, quantal spontaneous events, recorded in a cholinergic synapse, increased their amplitude, an effect which was independent of the anticholinesterasic activity associated with this compound. The anticholinesterasic effect was recorded in preparations treated with a galantamine concentration of 10 microM. 5. In conclusion, our results show that galantamine enhances human alpha7 neuronal nicotinic ACh receptor activity. It also enhances muscular AChRs and the size of spontaneous cholinergic synaptic events. However, only a very narrow range of galantamine concentrations can be used for enhancing effects.</description><subject>alpha7 Nicotinic Acetylcholine Receptor</subject><subject>Animals</subject><subject>Cholinesterase Inhibitors - pharmacology</subject><subject>Female</subject><subject>Galantamine - pharmacology</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Membrane Potentials - drug effects</subject><subject>Nootropic Agents - pharmacology</subject><subject>Oocytes - drug effects</subject><subject>Parasympathetic Nervous System - drug effects</subject><subject>Patch-Clamp Techniques</subject><subject>Receptors, Nicotinic - drug effects</subject><subject>Synapses - drug effects</subject><subject>Synaptic Transmission - drug effects</subject><subject>Torpedo</subject><subject>Xenopus laevis</subject><issn>0007-1188</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFOwzAMhnsAsTF4BZQTJyqlS9q0RzQNmDSJy-5V6jprUZqEJEXqU_GKlG2cudiy9H229V8lS0qpSLOsLBfJbQgflGZciPwmWWR5yTjnbJl8b5VCiMQqcpRamiiH3iCxhsQOSTcO0hCpXScFMTh6a6Qmpgcb-7kSCRgnDZ3Vv5JHQBetfzq5B-sdtvZfmkjTkuDsfNqgHQO5AP44K2Ey0sWTG_uvPk53ybWSOuD9pa-Sw8v2sHlL9--vu83zPnU5Z6kStAHZlIXiTLZlxQAAoQKWy0oI4FlZNFzhmkEDTLGWKZ4xPg8UmwKKhq2Sx_Na5-3niCHWQx8AtT7_WBeiqta0yGfw4QKOzYBt7Xw_SD_VfwmzHy50fZs</recordid><startdate>200507</startdate><enddate>200507</enddate><creator>Texidó, Laura</creator><creator>Ros, Esteve</creator><creator>Martín-Satué, Mireia</creator><creator>López, Susana</creator><creator>Aleu, Jordi</creator><creator>Marsal, Jordi</creator><creator>Solsona, Carles</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200507</creationdate><title>Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity</title><author>Texidó, Laura ; Ros, Esteve ; Martín-Satué, Mireia ; López, Susana ; Aleu, Jordi ; Marsal, Jordi ; Solsona, Carles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p543-f70bcab86f43ad893cccec9c35a977c4186b4fe23cbc3f3d3f4134cbc0eb6c6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>alpha7 Nicotinic Acetylcholine Receptor</topic><topic>Animals</topic><topic>Cholinesterase Inhibitors - pharmacology</topic><topic>Female</topic><topic>Galantamine - pharmacology</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Membrane Potentials - drug effects</topic><topic>Nootropic Agents - pharmacology</topic><topic>Oocytes - drug effects</topic><topic>Parasympathetic Nervous System - drug effects</topic><topic>Patch-Clamp Techniques</topic><topic>Receptors, Nicotinic - drug effects</topic><topic>Synapses - drug effects</topic><topic>Synaptic Transmission - drug effects</topic><topic>Torpedo</topic><topic>Xenopus laevis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Texidó, Laura</creatorcontrib><creatorcontrib>Ros, Esteve</creatorcontrib><creatorcontrib>Martín-Satué, Mireia</creatorcontrib><creatorcontrib>López, Susana</creatorcontrib><creatorcontrib>Aleu, Jordi</creatorcontrib><creatorcontrib>Marsal, Jordi</creatorcontrib><creatorcontrib>Solsona, Carles</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Texidó, Laura</au><au>Ros, Esteve</au><au>Martín-Satué, Mireia</au><au>López, Susana</au><au>Aleu, Jordi</au><au>Marsal, Jordi</au><au>Solsona, Carles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2005-07</date><risdate>2005</risdate><volume>145</volume><issue>5</issue><spage>672</spage><epage>678</epage><pages>672-678</pages><issn>0007-1188</issn><abstract>1. Various types of anticholinesterasic agents have been used to improve the daily activities of Alzheimer's disease patients. It was recently demonstrated that Galantamine, described as a molecule with anticholinesterasic properties, is also an allosteric enhancer of human alpha4beta2 neuronal nicotinic receptor activity. We explored its effect on the human alpha7 neuronal nicotinic acetylcholine receptor (nAChR) expressed in Xenopus oocytes. 2. Galantamine, at a concentration of 0.1 microM, increased the amplitude of acetylcholine (ACh)-induced ion currents in the human alpha7 nAChR expressed in Xenopus oocytes, but caused inhibition at higher concentrations. The maximum effect of galantamine, an increase of 22% in the amplitude of ACh-induced currents, was observed at a concentration of 250 microM Ach. 3. The same enhancing effect was obtained in oocytes transplanted with Torpedo nicotinic acetylcholine receptor (AChR) isolated from the electric organ, but in this case the optimal concentration of galantamine was 1 microM. In this case, the maximum effect of galantamine, an increase of 35% in the amplitude of ACh-induced currents, occurred at a concentration of 50 microM ACh. 4. Galantamine affects not only the activity of post-synaptic receptors but also the activity of nerve terminals. At a concentration of 1 microM, quantal spontaneous events, recorded in a cholinergic synapse, increased their amplitude, an effect which was independent of the anticholinesterasic activity associated with this compound. The anticholinesterasic effect was recorded in preparations treated with a galantamine concentration of 10 microM. 5. In conclusion, our results show that galantamine enhances human alpha7 neuronal nicotinic ACh receptor activity. It also enhances muscular AChRs and the size of spontaneous cholinergic synaptic events. However, only a very narrow range of galantamine concentrations can be used for enhancing effects.</abstract><cop>England</cop><pmid>15834443</pmid><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1188 |
ispartof | British journal of pharmacology, 2005-07, Vol.145 (5), p.672-678 |
issn | 0007-1188 |
language | eng |
recordid | cdi_proquest_miscellaneous_67992065 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; PubMed Central; Alma/SFX Local Collection |
subjects | alpha7 Nicotinic Acetylcholine Receptor Animals Cholinesterase Inhibitors - pharmacology Female Galantamine - pharmacology Humans In Vitro Techniques Membrane Potentials - drug effects Nootropic Agents - pharmacology Oocytes - drug effects Parasympathetic Nervous System - drug effects Patch-Clamp Techniques Receptors, Nicotinic - drug effects Synapses - drug effects Synaptic Transmission - drug effects Torpedo Xenopus laevis |
title | Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T07%3A04%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20galantamine%20on%20the%20human%20alpha7%20neuronal%20nicotinic%20acetylcholine%20receptor,%20the%20Torpedo%20nicotinic%20acetylcholine%20receptor%20and%20spontaneous%20cholinergic%20synaptic%20activity&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Texid%C3%B3,%20Laura&rft.date=2005-07&rft.volume=145&rft.issue=5&rft.spage=672&rft.epage=678&rft.pages=672-678&rft.issn=0007-1188&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E67992065%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67992065&rft_id=info:pmid/15834443&rfr_iscdi=true |